留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

肺结节的病理演进与分子影像研究进展

张敏,  张国建

downloadPDF
文章导航 > 分子影像学杂志  > 2023 >  46(4): 759-764
张敏, 张国建. 肺结节的病理演进与分子影像研究进展[J]. 分子影像学杂志, 2023, 46(4): 759-764. doi: 10.12122/j.issn.1674-4500.2023.04.32
引用本文: 张敏, 张国建. 肺结节的病理演进与分子影像研究进展[J]. 分子影像学杂志, 2023, 46(4): 759-764. doi: 10.12122/j.issn.1674-4500.2023.04.32
shu
ZHANG Min, ZHANG Guojian. Advances in the pathological evolution of pulmonary nodules and molecular imaging studies[J]. Journal of Molecular Imaging, 2023, 46(4): 759-764. doi: 10.12122/j.issn.1674-4500.2023.04.32
Citation: ZHANG Min, ZHANG Guojian. Advances in the pathological evolution of pulmonary nodules and molecular imaging studies[J]. Journal of Molecular Imaging, 2023, 46(4): 759-764. doi: 10.12122/j.issn.1674-4500.2023.04.32
shu

肺结节的病理演进与分子影像研究进展

doi: 10.12122/j.issn.1674-4500.2023.04.32
  • 1.

    内蒙古医科大学第一临床医学院，内蒙古 呼和浩特 010050

  • 2.

    内蒙古医科大学附属医院核医学科，内蒙古 呼和浩特 010050

  • 3.

    内蒙古自治区分子影像学重点实验室，内蒙古 呼和浩特 010050

基金项目: 国家自然科学基金（81960319）；内蒙古自然科学基金（2021MS08085）；内蒙古自治区高等学校青年科技英才支持计划（NJYT22002）；内蒙古医科大学致远人才计划（善学人才项目）（ZY0202037）
详细信息
    作者简介:

    张敏，在读硕士研究生，E-mail: 1336917162@qq.com

    通讯作者:

    张国建，博士，主任医师，E-mail: zhangguojian0820@163.com

Advances in the pathological evolution of pulmonary nodules and molecular imaging studies

  • 1.

    he First Clinical Medical College of Inner Mongolia Medical University, Hohhot 010050, China

  • 2.

    Department of Nuclear Medicine, Affifiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China

  • 3.

    Key Laboratory of Molecular Imaging, Inner Mongolia Autonomous Region, Hohhot 010050, China

Funds: Supported by National Natural Science Foundation of China (81960319)

    摘要
  • 摘要: 随着肺部低剂量CT的普及和大众健康意识的提高，肺结节的检出率大大提高，但良恶性判断仍然是目前影像学的难点和热点，早期明确诊断对于疾病治疗方案的选择和预后结果至关重要。目前影像学对肺结节的研究已经从形态学向分子影像学方向发展，分子影像学能够对活体进行细胞和分子水平的定性、定量、动态研究，在诊断肺结节中显示出重要价值和潜力。本文就不同病理类型肺结节的病理演进过程进行概述，并对几种不同类型的核医学分子影像显像剂作一综述。

     

    Abstract: As the prevalence of low-dose CT scans for the lungs continues to rise, coupled with the enhancement of public health awareness, there has been a significant surge in the detection rate of pulmonary nodules. However, discerning between benign and malignant cases remains a contemporary challenge and hot topic in radiology. It is crucial to establish an early definitive diagnosis for the proper selection of treatment plans and to anticipate prognosis outcomes. The current investigative focus in radiology concerning pulmonary nodules has evolved from morphology to molecular imaging. Molecular imaging is capable of conducting qualitative, quantitative, and dynamic studies at the cellular and molecular level in vivo, revealing its important value and potential in diagnosing pulmonary nodules. This paper provides an overview of the pathological progression of pulmonary nodules of different pathological types and reviews the latest research developments of several different types of nuclear medicine molecular imaging agents in pulmonary nodules.

     

    • HTML全文
    • 参考文献(54)
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49. doi: 10.3322/caac.21660
    [2] Hong QY, Wu GM, Qian GS, et al. Prevention and management of lung cancer in China[J]. Cancer, 2015, 121(Suppl 17): 3080-8.
    [3] Martín-Sánchez JC, Lunet N, González-Marrón A, et al. Projections in breast and lung cancer mortality among women: a Bayesian analysis of 52 countries worldwide[J]. Cancer Res, 2018, 78(15): 4436-42. doi: 10.1158/0008-5472.CAN-18-0187
    [4] Gao SG, Li N, Wang SH, et al. Lung cancer in people's republic of China[J]. J Thorac Oncol, 2020, 15(10): 1567-76. doi: 10.1016/j.jtho.2020.04.028
    [5] Chen KN. Commentary: Pay attention to low-risk populations for lung cancer, but cautiously interpret ground-glass nodules screened by low-dose computed tomography scan[J]. J Thorac Cardiovasc Surg, 2020, 160(3): 833-4. doi: 10.1016/j.jtcvs.2019.10.204
    [6] Zhang Y, Fu FQ, Chen HQ. Management of ground-glass opacities in the lung cancer spectrum[J]. Ann Thorac Surg, 2020, 110(6): 1796-804. doi: 10.1016/j.athoracsur.2020.04.094
    [7] Henschke CI, Yankelevitz DF. Ct screening for lung cancer[J]. Radiol Clin N Am, 2000, 38(3): 487-95. doi: 10.1016/S0033-8389(05)70179-2
    [8] Dalli A, Selimoglu Sen H, Coskunsel M, et al. Diagnostic value of PET/CT in differentiating benign from malignant solitary pulmonary nodules[J]. J BUON, 2013, 18(4): 935-41.
    [9] Ampel NM. The solitary pulmonary nodule[J]. New Eng J Med, 2003, 349(16): 1575.
    [10] Ye T, Deng L, Wang S, et al. Lung adenocarcinomas manifesting as radiological part-solid nodules define a special clinical subtype[J]. J Thorac Oncol, 2019, 14(4): 617-27. doi: 10.1016/j.jtho.2018.12.030
    [11] Sun K, You AJ, Wang B, et al. Clinical T1aN0M0 lung cancer: differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography[J]. Eur Radiol, 2021, 31(10): 7353-62. doi: 10.1007/s00330-021-07865-2
    [12] Kobayashi Y, Ambrogio C, Mitsudomi T. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights[J]. Transl Lung Cancer Res, 2018, 7(4): 487-97. doi: 10.21037/tlcr.2018.07.04
    [13] Godoy MCB, Naidich DP. Overview and strategic management of subsolid pulmonary nodules[J]. J Thorac Imaging, 2012, 27(4): 240-8. doi: 10.1097/RTI.0b013e31825d515b
    [14] Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society[J]. Radiology, 2013, 266(1): 304-17. doi: 10.1148/radiol.12120628
    [15] Qu R, Tu DH, Cai YX, et al. Clinical features and surgical outcomes of young patients with lung adenocarcinoma manifesting as ground glass opacity[J]. Front Oncol, 2022, 12: 979522. doi: 10.3389/fonc.2022.979522
    [16] Kawaguchi T, Koh Y, Ando M, et al. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study[J]. J Clin Oncol, 2016, 34(19): 2247-57. doi: 10.1200/JCO.2015.64.2322
    [17] 杨杨, 蔡兆诚, 曹源, 等. 双源双能量CT增强鉴别肺纯磨玻璃结节浸润前病变与浸润性病变[J]. 影像诊断与介入放射学, 2019, 28(2): 128-33. doi: 10.3969/j.issn.1005-8001.2019.02.009
    [18] 俞慧波, 陈中港, 李琼, 等. 月牙征预测纯磨玻璃结节肺腺癌浸润性的价值[J]. 中华放射学杂志, 2021, 55(4): 403-8. doi: 10.3760/cma.j.cn112149-20200609-00791
    [19] 刘禄, 杨娜, 杨槐, 等. 肺小细胞癌临床病理特征分析[J]. 临床医药实践, 2020, 29(7): 529-32. doi: 10.16047/j.cnki.cn14-1300/r.2020.07.019
    [20] Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects[J]. Eur Respir J, 2010, 35(1): 202-15. doi: 10.1183/09031936.00105009
    [21] Jett JR, Schild SE, Kesler KA, et al. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e400S-e419S.
    [22] MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the fleischner society 2017[J]. Radiology, 2017, 284(1): 228-43. doi: 10.1148/radiol.2017161659
    [23] Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition)[J]. Chest, 2007, 132(3 Suppl): 108-30.
    [24] Perrone A. Molecular imaging technologies and translational medicine[J]. J Nucl Med, 2008, 49(12): 25.
    [25] 骆殿存, 陶兴, 杨文魁, 等. 肺孤立性磨玻璃样结节浸润性与CT影像特征的相关性[J]. 河南医学研究, 2021, 30(29): 5384-7. doi: 10.3969/j.issn.1004-437X.2021.29.003
    [26] 王国鑫, 陆锡波. 恶性肿瘤患者伴发或新发孤立性肺结节的CT表现及诊断价值分析[J]. 中国基层医药, 2021, 28(10): 1560-3. doi: 10.3760/cma.issn1008-6706.2021.10.026
    [27] Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology[J]. Radiology, 2004, 231(2): 305-32. doi: 10.1148/radiol.2312021185
    [28] Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions[J]. J Nucl Med, 2007, 48(2): 214-20.
    [29] Ayesha S, Bryant, Msph M, et al. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules[J]. Ann Thorac Surg, 2006, 82(3): 1016-20. doi: 10.1016/j.athoracsur.2006.03.095
    [30] Hashimoto Y, Tsujikawa T, Kondo C, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5[J]. J Nucl Med, 2006, 47(3): 426-31.
    [31] Yi C, Lee K, Kim B, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT[J]. J Nucl Med, 2006, 47(3): 443-50.
    [32] Kwee TC, Cheng G, Lam MGEH, et al. SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions[J]. Eur J Nucl Med Mol Imaging, 2013, 40(10): 1475-7. doi: 10.1007/s00259-013-2484-x
    [33] Sim YT, Goh YG, Dempsey MF, et al. PET-CT evaluation of solitary pulmonary nodules: correlation with maximum standardized uptake value and pathology[J]. Lung, 2013, 191(6): 625-32. doi: 10.1007/s00408-013-9500-6
    [34] Thie J. Understanding the standardized uptake value, its methods, and implications for usage[J]. J Nucl Med, 2004, 45(9): 1431-4.
    [35] Yang P, Xu XY, Liu XJ, et al. The value of delayed (18)F FDG-PET imaging in diagnosis of solitary pulmonary nodules: a preliminary study on 28 patients[J]. Quant Imaging Med Surg, 2011, 1(1): 31-4.
    [36] 张利卜, 朱磊, 朱湘, 等. 18F-FDG PET/CT双时相显像代谢参数对孤立性肺结节的诊断价值[J]. 癌症, 2020, 39(12): 563-70. https://www.cnki.com.cn/Article/CJFDTOTAL-AIZH202012003.htm
    [37] Matthies A, Hickeson M, Cuchiara A, et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules[J]. J Nucl Med, 2002, 43(7): 871-5.
    [38] Ambrosini V, Nicolini S, Caroli P, et al. PET/CT imaging in different types of lung cancer: an overview[J]. Eur J Radiol, 2012, 81(5): 988-1001. doi: 10.1016/j.ejrad.2011.03.020
    [39] Sai KKS, Zachar Z, Bingham PM, et al. Metabolic PET imaging in oncology[J]. Am J Roentgenol, 2017, 209(2): 270-6. doi: 10.2214/AJR.17.18112
    [40] Gould MK, MacLean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions[J]. JAMA, 2001, 285(7): 914. doi: 10.1001/jama.285.7.914
    [41] Orlacchio A, Schillaci O, Antonelli L, et al. Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT[J]. Radiol Med, 2007, 112(2): 157-73. doi: 10.1007/s11547-007-0132-x
    [42] Klein JS, Braff S. Imaging evaluation of the solitary pulmonary nodule[J]. Clin Chest Med, 2008, 29(1): 15-38. doi: 10.1016/j.ccm.2007.11.007
    [43] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-37. doi: 10.1038/nm.3394
    [44] Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl Med, 2018, 59(9): 1423-9. doi: 10.2967/jnumed.118.210435
    [45] Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801-5. doi: 10.2967/jnumed.119.227967
    [46] Zhou XJ, Liu Q, Wada Y, et al. CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma[J]. Oncol Lett, 2017: 183-8.
    [47] Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment[J]. APMIS, 2008, 116(7/8): 695-715.
    [48] 王爽, 刘晓芳, 李眉, 等. 99Tcm-3PRGD2SPECT/CT在肺部良恶性病变中的诊断价值[J]. 中国医学影像技术, 2017, 33(10): 1512-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201710024.htm
    [49] Zhang R, Zhu L, Cai Z, et al. Potential feature exploration and model development based on 18F-FDG PET/CT images for differentiating benign and malignant lung lesions[J]. Eur J Radiol, 2019, 121: 108735. doi: 10.1016/j.ejrad.2019.108735
    [50] Kang F, Mu W, Gong J, et al. Integrating manual diagnosis into radiomics for reducing the false positive rate of. 18F-FDG PET/CT diagnosis in patients with suspected lung cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46(13): 2770-9. doi: 10.1007/s00259-019-04418-0
    [51] Xing Y, Chand G, Liu CC, et al. Early phase Ⅰ study of a 99mTc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer[J]. J Nucl Med, 2019, 60(9): 1213-20. doi: 10.2967/jnumed.118.224170
    [52] Hu ZH, Fang C, Li B, et al. First-in-human liver-tumour surgery guided by multispectral fluorescence imaging in the visible and near-infrared-Ⅰ/Ⅱ windows[J]. Nat Biomed Eng, 2020, 4(3): 259-71.
    [53] Yu ZP, Hu M, Li ZQ, et al. Anti-G250 nanobody-functionalized nanobubbles targeting renal cell carcinoma cells for ultrasound molecular imaging[J]. Nanotechnology, 2020, 31(20): 205101. doi: 10.1088/1361-6528/ab7040
    [54] Prantner AM, Yin C, Kamat K, et al. Molecular imaging of mesothelin-expressing ovarian cancer with a human and mouse cross-reactive nanobody[J]. Mol Pharmaceutics, 2018, 15(4): 1403-11. doi: 10.1021/acs.molpharmaceut.7b00789
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  135
  • HTML全文浏览量:  33
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-02-18
  • 网络出版日期:  2023-07-18
  • 刊出日期:  2023-07-20

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日